Organon & Co. (OGN)
NYSE: OGNHealth CareBiotechnology: Pharmaceutical PreparationsUSD
At close: Oct 7, 4:00 PM ET · Delayed 15 min
OGN stock chart
Technical analysisKey statistics
All statistics- Market cap
- $3.62B
- P/E (TTM)
- 17.68
- Forward P/E
- 3.81
- EPS (TTM)
- $0.78
- Dividend yield
- 0.58% ($0.08)
- Ex-dividend date
- Aug 14, 2026
- 52-week range
- 5.69 – 13.79
- Day range
- 13.72 – 13.79
- Volume / Avg
- 2.21M / 2.64M
- Beta
- —
- Shares outstanding
- 262.61M
52-week range
OGN stock today
Shares of Organon (OGN) finished higher on Oct 7 at $13.79, a gain of 0.36% or $0.05 per share, versus the S&P 500's 0.22% decline. The stock is trading at or near its 52-week high of $13.79, set on Oct 7, 2026, 142.4% above the 52-week low of $5.69. OGN is up 92.3% year to date, outperforming the S&P 500 (+14.0%). Over the past 12 months, the stock has gained 30.1%.
Organon trades at 17.7x its trailing twelve-month earnings per share of $0.78. Its forward P/E of 3.8x is lower than the trailing multiple, which means analysts expect earnings to rise over the next year. Organon pays an annual dividend of $0.08 per share, a 0.58% yield at the current price.
Summary generated from market data by MetaCap's automated system. Methodology
About Organon
Company profileOrganon & Co. develops and delivers women health solutions through prescription therapies and medical devices in the United States, Europe, Canada, Japan, rest of the Asia Pacific, China, Latin America, the Middle East, Russia, Africa, and internationally. The company's women's health portfolio comprises contraception and fertility brands, such as Nexplanon, a long-acting reversible contraceptive; NuvaRing, a monthly vaginal contraceptive ring; Cerazette, Marvelon, and Mercilon to prevent pregnancy; Follistim AQ, which is used to promote development of ovarian follicles; Elonva, a follicle stimulant; Ganirelix acetate injection, an injectable antagonist; Jada for abnormal postpartum uterine bleeding and hemorrhage; and Xaciato for bacterial vaginosis.
- Sector
- Health Care
- Industry
- Biotechnology: Pharmaceutical Preparations
- CEO
- Mr. Joseph T. Morrissey Jr.
- Headquarters
- Jersey City, NJ
- Employees
- 10,000
- IPO year
- 2021
- Website
- organon.com
Financial highlights
Full financialsIn fiscal 2025, Organon generated $6.22 billion in revenue, down 2.9% from fiscal 2024, its first annual decline since 2022. Net income was $187.0 million (-78.4% year over year), for a net margin of 3.0% versus a median of 16.3% in the prior 5 years. Gross margin was 53.3% (down from 58.0%).
| Fiscal year | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|
| Revenue | $6.22B | $6.40B | $6.26B | $6.17B | $6.30B |
| Growth | -2.92% | +2.24% | +1.44% | -2.06% | -3.49% |
| Net income | $187.00M | $864.00M | $1.02B | $917.00M | $1.35B |
| EPS (diluted) | $0.72 | $3.33 | $3.99 | $3.59 | $5.31 |
Analyst forecast
ForecastConsensus (5 analysts)
none
Avg. price target
$11.25-18.42%
- Strong buy 0
- Buy 0
- Hold 4
- Sell 0
- Strong sell 1
Target range
Ratings and targets reflect third-party analyst opinions, not MetaCap recommendations.
Earnings
Earnings history- Last reported (Q2 2026)
- Jul 31, 2026
- EPS actual vs est.
- $0.40 vs —
Dividends
Dividend history- Annual dividend
- $0.08
- Dividend yield
- 0.58%
- Last payment
- $0.02
- Ex-dividend date
- Aug 14, 2026
OGN news
All OGN newsOrganon peers
Health Care sector| Company | Price | % Chg | Market cap | Compare |
|---|---|---|---|---|
| VKTXViking Therapeutics Inc. | 28.54 | +0.56% | $3.63B | vs OGN |
| PBLSParabilis Medicines Inc. | 28.82 | -0.14% | $3.56B | vs OGN |
| TNGXTango Therapeutics Inc. | 21.83 | -0.32% | $3.68B | vs OGN |
| XENEXenon Pharmaceuticals Inc. | 36.41 | -0.44% | $3.53B | vs OGN |
| IDYAIDEAYA Biosciences Inc. | 36.26 | -1.01% | $3.50B | vs OGN |
| LEGNLegend Biotech Corporation ADR | 19.12 | +2.14% | $3.72B | vs OGN |
| AMLXAmylyx Pharmaceuticals Inc. | 27.43 | -2.18% | $3.44B | vs OGN |
| TLXTelix Pharmaceuticals Limited ADR | 11.12 | +3.15% | $3.78B | vs OGN |
Indexes, lists and sector
Appears in lists
Organon stock FAQ
What is Organon's stock price today?
OGN last traded at $13.79 as of Oct 7, 4:00 PM EDT, up 0.36% on the day. Prices are delayed at least 15 minutes.
Does Organon pay a dividend?
Yes. Organon pays $0.08 per share annually, a 0.58% yield. The most recent dividend of $0.02 had an ex-dividend date of Aug 14, 2026.
What is OGN's P/E ratio?
OGN trades at a trailing P/E ratio of 17.68 and a forward P/E of 3.81.
Who is Organon's CEO?
Mr. Joseph T. Morrissey Jr. is the chief executive officer of Organon & Co., which has about 10,000 employees.
What is the OGN 52-week high?
The 52-week high for OGN is $13.79 and the 52-week low is $5.69. The stock is currently 0.0% below its high.